Cannabidiol (CBD) for Anxiety: Real Use Against Limited, Mixed Evidence
A patient self-treating his anxiety with unmeasured over-the-counter CBD asks if he should just skip prescription medication altogether. The honest answer runs into both a genuinely mixed evidence base and a largely unregulated supplement market.
Ben H., a 27-year-old man, has mild-to-moderate generalized anxiety disorder and has been taking an over-the-counter CBD tincture, purchased online, for the past three months at a dose he estimates but has never precisely measured. He reports it "takes the edge off" without any of the daytime sedation he experienced on a brief prior trial of hydroxyzine, and asks his physician directly whether he should just continue with the CBD instead of starting a prescription medication, since it's "natural" and available without a prescription.
CBD's anxiolytic evidence is genuinely mixed and considerably thinner than any FDA-approved anxiety treatment — some controlled trials show real anxiolytic effect, particularly at doses well above what most over-the-counter products actually contain, while others show no meaningful difference from placebo. Critically, the supplement market is essentially unregulated for potency and purity: independent testing of over-the-counter CBD products has repeatedly found significant mislabeling, with actual CBD content often well below, and occasionally well above, what's stated on the label, along with inconsistent or absent screening for contaminants.
He mentions he chose this particular brand because of positive reviews on a forum dedicated to anxiety management, not because of any lab-testing certificate or third-party verification, and hadn't previously considered that a product's popularity online says nothing about whether its label accurately reflects what's actually in the bottle.
He also volunteers that he's never mentioned the CBD use to any physician before today, assuming it wasn't relevant since it's sold openly and doesn't require a prescription — a gap in disclosure the team notes is common with supplement use generally, and worth normalizing as something to always ask about directly rather than wait for patients to bring up.
An unregulated product against an evidence-based alternative
The honest answer is that CBD's anxiolytic evidence is real but genuinely mixed, and most of the positive trial data used doses well above what over-the-counter tinctures typically contain — he may be getting a placebo-adjacent dose, a therapeutic one, or something in between, and there's no reliable way to know from an unregulated product.
The bigger practical problem isn't just underdosing, it's that independent testing of over-the-counter CBD products has repeatedly found real mislabeling — some products test far below stated potency, others above, and contaminant screening is inconsistent across brands. He's not choosing between a known dose of CBD and a prescription option; he's choosing an unknown quantity of an inconsistently regulated product.
I don't want to dismiss that he feels it's helping — that's real and worth taking seriously, not just as placebo. But for his level of symptom severity, an SSRI has a far deeper, more consistent evidence base and known, standardized dosing. My recommendation is to offer an SSRI trial while being honest that if he wants to continue CBD alongside it, or instead of it, that's his informed choice to make once he understands the regulatory gap clearly.
If he does run the two together, one more thing belongs in that informed choice: CBD inhibits CYP2C19 and CYP3A4, and can raise SSRI concentrations. The effect is best documented for citalopram and escitalopram, where added CBD measurably increased plasma levels; the in vitro signal for sertraline is weaker, but a case of hyponatremia and cognitive change after CBD was added to stable sertraline has been reported. Combined with an unverified product potency, that argues for watching for the usual dose-related SSRI effects rather than assuming a supplement can't move a prescription drug's levels.
Agreed: the regulatory and evidence gaps around over-the-counter CBD were explained directly. Ben elected to try an SSRI trial while deciding separately whether to continue the CBD tincture alongside it, understanding neither the dose nor the product's actual content is verified.